Key result
Nearly 1 in 4 women treated with doxorubicin and trastuzumab for breast cancer develop left ventricular systolic dysfunction, highlighting the need for early detection via non-invasive cardiac imaging.
This review highlights the high rate of left ventricular systolic dysfunction in breast cancer patients treated with doxorubicin and trastuzumab and explores non-invasive imaging for early detection.
Supports monitoring for LV dysfunction in this setting; hypothesis-generating for imaging-guided strategies pending prospective trials.
Although breast cancer is one of the leading causes of death in women worldwide, there is an overall improvement in the survival of this patient population. This is likely due to a combination of early detection through screening and awareness, improved targeted biological therapy, and an overall improvement in disease management. Despite the beneficial effects of the 2 anti-cancer drugs doxorubicin (DOX) and trastuzumab (TRZ) in women with breast cancer, development of cardiotoxicity is a major concern. The occurrence of left ventricular systolic dysfunction is unacceptably high in nearly 1 in 4 women treated with DOX+TRZ in the breast cancer setting. In this review, we explore the use of non-invasive cardiac imaging for the early detection of chemotherapy-mediated cardiotoxicity in women with breast cancer, in the hope of preventing end-stage heart disease in this cancer population.
No takes yet. Share an insight, caveat, or question.
Saeed et al. (2014) conducted a review in Breast cancer and chemotherapy-mediated cardiotoxicity. Non-invasive cardiac imaging was evaluated. Nearly 1 in 4 women treated with doxorubicin and trastuzumab for breast cancer develop left ventricular systolic dysfunction, highlighting the need for early detection via non-invasive cardiac imaging.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: